Company research / WST

West Pharmaceutical Services Inc (WST)

SEC name WEST PHARMACEUTICAL SERVICES INC · CIK 0000105770 · NYSE · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated PA
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, West Pharmaceutical Services Inc reported revenue of $3.07B. Revenue grew 6.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $3.33B.

Key ratios (year ended 2025-12-31)

35.9%
Gross margin
19.0%
Operating margin
16.1%
Net margin
15.5%
Return on year-end equity
6.3%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 2-for-1, first reflected in a filing dated 2013-11-04. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$3.33B$3.07B$2.89B$2.95B$2.89B$2.83B$2.15B$1.84B$1.72B$1.60B$1.51B
Cost of Revenue$2.10B$1.97B$1.89B$1.82B$1.75B$1.66B$1.38B$1.23B$1.17B$1.09B$1.01B
Gross Profit$1.22B$1.10B$998.50M$1.13B$1.14B$1.18B$767.80M$605.70M$545.40M$512.90M$501.40M
R&D Expense$74.40M$74.30M$69.10M$68.40M$58.50M$52.80M$46.90M$38.90M$40.30M$39.10M$36.80M
Operating Income$680.40M$584.90M$569.90M$676.00M$734.00M$752.30M$406.90M$296.60M$240.30M$225.80M$195.20M
Depreciation & Amortization$181.40M$171.40M$155.40M$137.30M$120.60M$122.30M$109.10M$103.40M$104.40M$96.70M$90.70M
EBITDA$861.80M$756.30M$725.30M$813.30M$854.60M$874.60M$516.00M$400.00M$344.70M$322.50M$285.90M
Net Income$564.90M$493.70M$492.70M$593.40M$585.90M$661.80M$346.20M$241.70M$206.90Mn/an/a
EPS (Diluted)n/a$6.79$6.69$7.88$7.73$8.67$4.57$3.21$2.74$1.99$1.91
Total Assets$4.08B$4.27B$3.64B$3.83B$3.62B$3.31B$2.79B$2.34B$1.98B$1.86B$1.72B
Total Liabilities$1.09B$1.09B$961.10M$948.50M$931.90M$978.40M$939.30M$768.20M$582.60M$582.90M$599.20M
Long-Term Debt$202.90M$202.80M$202.60M$206.80M$208.90M$253.00M$255.20M$257.30M$196.10M$197.00M$228.60M
Shareholders' Equity$2.99B$3.18B$2.68B$2.88B$2.68B$2.34B$1.85B$1.57B$1.40B$1.28B$1.12B
Cash & Equivalents$435.80M$791.30M$484.60M$853.90M$894.30M$762.60M$615.50M$439.10M$337.40M$235.90M$203.00M
Operating Cash Flow$662.20M$754.80M$653.40M$776.50M$724.00M$584.00M$472.50M$367.20M$288.60M$263.30M$219.40M
Capital Expenditures$225.30M$285.90M$377.00M$362.00M$284.60M$253.40M$174.40M$126.40M$104.70M$130.80M$170.20M
Free Cash Flow$436.90M$468.90M$276.40M$414.50M$439.40M$330.60M$298.10M$240.80M$183.90M$132.50M$49.20M
Share Repurchases$454.30M$134.00M$560.90M$438.30M$202.80M$137.10M$115.50M$83.10M$70.80M$74.40M$52.20M
Dividends Paid$62.40M$61.20M$59.10M$57.00M$54.10M$51.10M$48.10M$45.10M$42.10M$39.10M$35.80M
Shares Outstanding70.40M72.00M72.30M73.50M74.10M74.20M74.00M74.10M74.10M73.90M73.10M
Dividends Per Sharen/a$0.86$0.82$0.78$0.74$0.70$0.66$0.62$0.58$0.54$0.50
Weighted Average Diluted Sharesn/a72.70M73.70M75.30M75.80M76.30M75.80M75.40M75.40M75.80M75.00M
EPS (Basic)n/a$6.83$6.75$7.98$7.87$8.89$4.68$3.27$2.80$2.04$1.96

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView